Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1261253 | 0.71 | MAOA (0.35) | MAOAMAOBFTOKDM4ECA1 | |
| SCHEMBL8394661 | 0.67 | — | — | |
| SCHEMBL2979159 | 0.65 | ALDH1A1 (0.32) | MAOAALDH1A1MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL466442 | 0.65 | MAOB (0.47) | MAOAMAOBFTOALDH1A1MAPT | |
| SCHEMBL2514183 | 0.64 | ELANE (0.32) | MAOAALDH1A1MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL1743358 | 0.63 | ALDH1A1 (0.42) | ALDH1A1MAPTHSD17B10LMNATP53 | |
| SCHEMBL29225951 | 0.61 | — | — | |
| SCHEMBL578709 | 0.61 | CYP2A6 (0.32) | ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL7414230 | 0.60 | CA1 (0.37) | MAOAALDH1A1MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL24891350 | 0.59 | ELANE (0.61) | MAOAALDH1A1MAPTSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005593-A | Preparation method of 2, 3-disubstituted chromone compound | 昆明理工大学 | 2024-05-10 | — | — | CN | claimed |
| CN-112105354-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2020-12-18 | — | — | CN | claimed |
| EP-3723753-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2020-10-21 | — | — | EP | claimed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | claimed |
| WO-2019118932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2019-06-20 | — | — | WO | claimed |
| US-6388081-B1 | 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | LION BIOSCIENCE AG (DE) | 2002-05-14 | — | — | US | claimed |
| EP-0983507-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| CN-118005593-A | Preparation method of 2, 3-disubstituted chromone compound | 昆明理工大学 | 2024-05-10 | — | — | CN | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-112105354-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3723753-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2019-06-20 | — | — | WO | disclosed |
| US-5780209-A | Processing of photographic silver halide photosensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5582962-A | COLLOID LAYERS COMPRISING A DISPERSE DYE PARTICLES | KONICA CORPORATION (JP) | 1996-12-10 | — | — | US | disclosed |
| EP-0679935-A2 | Silver halide photographic light-sensitive material and the processing method thereof | KONICA CORPORATION (JP) | 1995-11-02 | — | — | EP | disclosed |
| US-5340707-A | Containing specified pyrazolone dye; storage stability | KONICA CORPORATION (JP) | 1994-08-23 | — | — | US | disclosed |
| US-4694002-A | Benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1987-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | MAOA 3475/4885MAOB 3340/4885FTO 4161/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | MAOA 3475/4885MAOB 3340/4885FTO 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.